NBY · Novabay Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | $479.0K | - | - | - | $848.0K | $808.0K | $837.0K | - |
| Gross Profit | - | - | $42.0K | - | - | - | $1.59M | $1.59M | $1.79M | - |
| R&D | - | - | - | - | - | - | $4.0K | $9.0K | $19.0K | - |
| SG&A | $2.85M | - | $1.21M | $1.89M | $2.70M | - | $1.70M | $1.62M | $2.29M | - |
| Total Operating Expenses | $2.85M | - | $1.30M | $1.89M | $3.29M | - | $2.65M | $2.65M | $4.23M | - |
| D&A | - | - | $1.0K | $1.0K | $2.0K | - | $9.0K | $13.0K | $12.0K | - |
| Operating Income | $22.29M | - | ($1.26M) | ($1.89M) | ($3.29M) | - | ($1.06M) | ($1.05M) | ($2.44M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $3.45M | - | $0 | $0 | $0 | - | - | - | - | - |
| Net Income | $552.40M | - | ($1.29M) | ($1.92M) | $7.67M | - | ($1.21M) | ($1.58M) | ($3.21M) | - |
| EPS - Basic | $21.23 | - | ($1.10) | ($1.65) | $7.20 | - | ($3.00) | ($6.85) | ($26.25) | - |
| EPS - Diluted | $3.33 | - | ($9.60) | ($1.65) | ($149.75) | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18.41M | $7.96M | $2.31M | $5.34M | $8.47M | $430.0K | $776.0K | $751.0K | $1.82M | $3.13M |
| Accounts Receivable | - | - | - | - | - | - | $704.0K | $547.0K | $734.0K | $759.0K |
| Inventory | - | - | - | $467.0K | - | $765.0K | $473.0K | $700.0K | $663.0K | $2.88M |
| Accounts Payable | $1.98M | $257.0K | $76.0K | $604.0K | $800.0K | $623.0K | $396.0K | $1.24M | $1.12M | $1.13M |
| Current Assets | $19.05M | $8.68M | $2.90M | $6.12M | $9.04M | $1.94M | $2.28M | $2.25M | $3.59M | $7.15M |
| Total Assets | $179.74M | $9.04M | $3.49M | $6.91M | $9.87M | $3.42M | $3.88M | $3.92M | $5.36M | $9.03M |
| Current Liabilities | $3.58M | $1.14M | $1.45M | $2.14M | $3.07M | $2.84M | $1.98M | $3.61M | $3.92M | $4.28M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $40.92M | $31.86M | $1.85M | $2.67M | $3.71M | $3.55M | $2.81M | $4.54M | $5.20M | $5.72M |
| Stockholders' Equity | $138.82M | ($23.18M) | $1.11M | $4.25M | $6.17M | ($129.0K) | $1.07M | ($617.0K) | $160.0K | $3.31M |
| Retained Earnings | ($266.65M) | ($210.41M) | ($183.82M) | ($177.71M) | ($175.79M) | ($183.46M) | ($182.25M) | ($180.03M) | ($178.44M) | ($174.85M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.80M) | - | - | - | ($1.32M) | - | - | - | ($1.57M) | - |
| Investing Cash Flow | ($25.92M) | - | - | - | $0 | - | - | - | $1.07M | - |
| Financing Cash Flow | $38.34M | - | - | - | ($1.71M) | - | - | - | ($597.0K) | - |
| CapEx | - | - | - | - | $0 | - | - | - | $2.0K | - |
| Free Cash Flow | - | - | - | - | ($1.32M) | - | - | - | ($1.57M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | -0.17 | - | - | - | 0.49 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | 0.6% | - | - | - | 0.0% | - | - | - | - | - |
| Return on assets | 307.3% | - | -37.1% | -27.8% | 77.7% | - | -31.3% | -40.4% | -60.0% | - |
| Return on equity | 397.9% | - | -116.6% | -45.3% | 124.4% | - | -113.1% | 256.9% | -2008.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 5.33 | 7.60 | 2.00 | 2.85 | 2.95 | 0.68 | 1.15 | 0.62 | 0.92 | 1.67 |
| Quick ratio | 5.33 | 7.60 | 2.00 | 2.63 | 2.95 | 0.41 | 0.91 | 0.43 | 0.75 | 1.00 |
| Cash ratio | 5.15 | 6.97 | 1.59 | 2.49 | 2.76 | 0.15 | 0.39 | 0.21 | 0.46 | 0.73 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.29 | -0.39 | 3.14 | 1.63 | 1.60 | -26.53 | 3.62 | -6.36 | 33.48 | 2.73 |
| Liabilities / Assets | 0.23 | 3.53 | 0.53 | 0.39 | 0.38 | 1.04 | 0.72 | 1.16 | 0.97 | 0.63 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | 1.79 | 1.15 | 1.26 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | 204d | 316d | 289d | - |
| Days payable outstanding | - | - | 58d | - | - | - | 170d | 558d | 487d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 0.4x | - | - | - | - | - | - | - | - | - |
| P / B | 1.8x | - | 6.7x | 0.8x | 0.1x | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | -97.4% | - | - | - | -13.3% | -31.0% | -7.3% | - |
| Operating income growth (YoY) | - | - | -18.4% | -79.6% | -35.1% | - | 4.9% | 22.3% | -40.5% | - |
| Net income growth (YoY) | 7102.1% | - | -6.7% | -21.3% | - | - | 31.0% | 22.2% | -84.8% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | 15.9% | - | - | - | 3.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 2151.1% | -17865.9% | 3.5% | - | 3754.4% | - | -84.8% | - | -98.2% | -68.6% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing NovaBay Pharmaceuticals against the 5 most active filers in the same SIC group.
Dividends
$4.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Sep 30, 2025 | $4.0000 |